IO Biotech Inc
IOBT
Company Profile
Business description
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Contact
Ole Maaloes Vej 3
Copenhagen NDK-2200
DNKT: +45 70702980
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
78
Stocks News & Analysis
stocks
This might be the best core stock bargain in the US market today
Patient investors should consider building a position in this wide-moat stock while it’s seriously undervalued.
stocks
Data center demand drives strong earnings outlook for SGM
Sims guides huge earnings upgrade as data center metals demand spikes.
stocks
Chart of the Week: AI proving a threat to company moats
The latest insights on AI from our equity research team.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,628.30 | 34.80 | -0.40% |
| CAC 40 | 7,684.48 | 123.39 | -1.58% |
| DAX 40 | 22,431.11 | 408.45 | -1.79% |
| Dow JONES (US) | 45,740.22 | 281.21 | -0.61% |
| FTSE 100 | 9,937.10 | 126.40 | -1.26% |
| HKSE | 25,277.32 | 223.26 | -0.88% |
| NASDAQ | 21,806.11 | 284.59 | -1.29% |
| Nikkei 225 | 53,372.53 | 1,866.87 | -3.38% |
| NZX 50 Index | 12,989.99 | 325.61 | -2.45% |
| S&P 500 | 6,548.24 | 58.25 | -0.88% |
| S&P/ASX 200 | 8,428.40 | 43.90 | -0.52% |
| SSE Composite Index | 3,957.05 | 49.50 | -1.24% |